Shares jumped 16.4% as Curaleaf delivered revenue growth that outpaced guidance and internal expectations, driven by strength in its international segment and supportive regulatory developments.
- Q1 revenue rose 6% year-over-year to $324 million, beating guidance and internal forecasts.
- International segment revenue surged 35%, highlighting the growing importance of Curaleaf’s global platform.
- Gross margin stood at 49%, with adjusted EBITDA of $63 million representing a 20% margin, despite a 170 basis point margin drag from international investments.
- Net income from continuing operations was $70 million ($0.09 per share), a significant turnaround from last year’s loss of $50 million.
- Regulatory progress, including medical cannabis rescheduling and potential 280E tax relief, underpinned investor enthusiasm and improved liquidity with a $500 million refinancing facility.
Community Discussion